Dr. Reddy’s Laboratories has launched Hervycta (trastuzumab), a biosimilar of Roche’s Herceptin, in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer).
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Dr. Reddy’s Hervycta is available in strengths of 150mg and 440mg multiple dose vials.
“We strive every day to do what matters most for patients. Hervycta is a step forward in our effort to accelerate access to cancer patients in India, in the Oncology biosimilar space,” MV Ramana, CEO-Branded Markets (India and Emerging Markets), Dr. Reddy’s Laboratories, said.
Herceptin (marketed as Herclon in India) and its biosimilars had India sales of approximately INR 290 Crore MAT for the most recent twelve months ending in December 2017, according to Ipsos.
Dr. Reddy’s currently has four biosimilar products commercialized in India and various emerging markets, and an active pipeline of several biosimilar products in the oncology and immunology space.